Also separately, Lilly said it would increase its dividend by 10.6% to 47 cents a share, affecting an increase in the annual dividend rate to $1.88 a share. Lilly was trading up 72 cents, or 1.3%, at $53.87.
In another deal,
(PHG - Get Report)
said it would buy health-care information company
for $430 million, or $12 a share. The price is a 35% premium to Visicu's closing price on December 17. Visicu makes remote monitoring technology and clinical intelligence products. The company's board unanimously approved the deal, which is now subject to shareholder vote. The transaction is expected to close in the first quarter of next year.
Visicu added $2.88, or 32.5%, to $11.74. Royal Philips was trading up 58 cents, or 1.4%, at $42.90.
said that it entered into an agreement with Ethicon Endo-Surgery granting exclusive rights to the company's patents and patent applications related to vagus nerve stimulation (VNS) for the treatment of obesity, diabetes and hypertension in overweight patients. Ethicon Endo-Surgery will pay Cyberonics a signing fee of $9.5 million and royalties on commercial sales of products covered by the subject patents. Cyberonics' were up 42 cents, or 3.6%, to $12.11.
said the results of its late stage trial on its Celacade System in patients with chronic heart failure have been accepted for publication in The Lancet. The company previously announced that the Celacade therapy reduced the risk of death or cardiovascular hospitalizations for a large pre-specified subgroup of patients with heart failure by 39% compared to placebo. Shares were trading up 35 cents, or 19.7%, at $2.13.